CA2525970C - Use of nilvadipine for reducing amyloid deposition, amyloid neurotoxicity and microgliosis - Google Patents
Use of nilvadipine for reducing amyloid deposition, amyloid neurotoxicity and microgliosis Download PDFInfo
- Publication number
- CA2525970C CA2525970C CA2525970A CA2525970A CA2525970C CA 2525970 C CA2525970 C CA 2525970C CA 2525970 A CA2525970 A CA 2525970A CA 2525970 A CA2525970 A CA 2525970A CA 2525970 C CA2525970 C CA 2525970C
- Authority
- CA
- Canada
- Prior art keywords
- nilvadipine
- administration
- human
- use according
- amyloid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Neurosurgery (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Epidemiology (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Steroid Compounds (AREA)
- Hydrogenated Pyridines (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Medicinal Preparation (AREA)
Abstract
The present invention provides methods for reducing b-amyloid deposition, b-amyloid neurotoxicity and microgliosis in animals or humans afflicted with a cerebral amyloidogenic disease, such as Alzheimer's disease (AD), by administering therapeutically effective amounts of the dihydropyridine calcium channel antagonist, nilvadipine. The present invention also provides methods for diagnosing cerebral amyloidogenic diseases in animals or humans. Further provided are methods for reducing the risk of b-amyloid deposition, b-amyloid neurotoxicity and microgliosis in animals or humans suffering from traumatic brain injury by administering nilvadipine immediately after the traumatic brain injury and continuing treatment for a prescribed period of time thereafter. Finally, methods are provided for treating transplantable neuronal stem cells by administering nilvadipine to the neuronal stem cells prior to transplantation in the central nervous system of an animal or human afflicted with a cerebral amyloidogenic disease, such as AD.
Description
USE OF NILVADIPINE FOR REDUCING AMYLOID DEPOSITION, AMYLOID NEUROTOXICITY AND MICROGLIOSIS
BACKGROUND OF THE INVENTION
Field of the Invention [00011 'fie present invention relates to a method for treating the pathophysiological effects of cerebral amyloidogenic diseases, such as Alzheimer's disease. More specifically, the method involves administering a specific dihydropyridine antagonist calcium channel blocker, nilvadipine, which opposes such pathophysiological effects in the brain of animals or humans afflicted with diseases associated with cerebral amyloidosis, such as Alzheimer's disease.
Description of Related Art [0002] Alzheimer's disease (AD) is the most common neurodegenerative disorder of aging, afflicting approximately 1% of the population over the age of 65.
Characteristic features of the disease include the progressive accumulation of intracellular neurofibrillary tangles, extracellular parenchymal senile plaques, and cerebrovascular deposits in the brain.
The principal component of senile plaques and cerebrovascular deposits is the 39-43 amino acid (3-amyloid peptide (AR), which is proteolytically derived from amyloid precursor protein (APP), a transmembrane glycoprotein.
100031 APP is a single-transmembrane protein with a 590-680 amino acid extracellular amino terminal domain and an approximately 55 amino acid cytoplasmic tail.
Messenger RNA from the APP gene on chromosome 21 undergoes alternative splicing to yield eight possible isoforms, three of which (the 695, 751 and 770 amino acid isoforms) predominate in the brain. APP undergoes proteolytic processing via three enzymatic activities, termed a-, 0-and y-secretase. Alpha secretase cleaves APP at amino. acid 17 of the AD
domain, thus releasing the large soluble amino-terminal fragment a-APP for secretion.
Because a-secretase cleaves within the AD domain, this cleavage precludes A(3 formation.
Alternatively, APP can be cleaved by (3-secretase to define the amino terminus of A(3 and to generate the soluble amino-terminal fragment (3-APP. Subsequent cleavage of the intracellular carboxy-terminal domain of APP by y-secretase results in the generation of multiple peptides, the two most common being 40-amino acid A(3 (A(340) and 42-amino acid A(3 (A1342).
comprises 90-95% of the secreted A(3 and is the predominant species recovered from cerebrospinal fluid (Seubert et at., Nature, 359:325-7, 1992). In contrast, less than 10% of secreted A(3 is A(342. Despite the relative paucity of AR42 production, A(342 is the predominant species found in plaques and is deposited initially, perhaps due to its ability to form insoluble amyloid aggregates more rapidly than A(340 (Jarrett et al., Biochemistry, 32:4693-7, 1993). The abnormal accumulation of A[3 in the brain is believed due to either over-expression or altered processing of APP.
[0004] A(3 peptides are thus believed to play a critical role in the pathobiology of AD, as all the mutations associated with the familial form of AD result in altered processing of these peptides from APP. Indeed, deposits of insoluble, or aggregated, fibrils of A(3 in the brain are a prominent neuropathological feature of all forms of AD, regardless of the genetic predisposition of the subject.
[0005] Concomitant with A[3 deposition, there exists robust activation of inflammatory pathways in AD brain, including production of pro-inflammatory cytokines and acute-phase reactants in and around A[3 deposits (McGeer et al., J. Leukocyte Biol., 65:409-15, 1999).
Activation of the brain's resident innate immune cells, the microglia, is thought to be intimately involved in this inflammatory cascade. It has been demonstrated that reactive microglia produce pro-inflammatory cytokines, such as inflammatory proteins and acute phase reactants, such as alpha-1-antichymotrypsin, transforming growth factor (3, apolipoprotein E and complement factors, all of which have been shown to be localized to A(3 plaques and to promote A(3 plaque "condensation" or maturation (Nilsson et al., J Neurosci.
21:1444-5, 2001), and which at high levels promote neurodegeneration.
Epidemiological studies have shown that patients using non-steroidal anti-inflammatory drugs (NSAIDS) have as much as a 50% reduced risk for AD (Rogers et al., Neurobiol. Aging 17:681-6, 1996), and post-mortem evaluation of AD patients who underwent NSAID treatment has demonstrated that risk reduction is associated with diminished numbers of activated microglia (Mackenzie et al., Neurology 50:986-90, 1998). Further, when Tg APPSW mice, a mouse model for Alzheimer's disease, are given an NSAID (ibuprofen), these animals show reduction in A(3 deposits, astrocytosis, and dystrophic neurites correlating with decreased microglial activation (Lim et al., J. Neurosci. 20:5709-14, 2000).
[0006] Products of the inflammatory process in the AD brain therefore may exacerbate AD
pathology. Furthermore, there is evidence that activated microglia in AD
brain, instead of clearing A(3, are pathogenic by promoting A(3 fibrillogenesis and consequent deposition as senile plaques (Wegiel et al., Acta Neuropathol. (Berl.) 100:356-64, 2000).
[0007] It also has been suggested that AD pathogenesis is due to the neurotoxic properties of AR. The cytotoxicity of A13 was first established in primary cell cultures from rodent brains and also in human cell cultures. The work of Mattson et al. (J.
Neurosci., 12:376-389, 1992) indicates that A(3, in the presence of the excitatory neurotransmitter glutamate, causes an immediate pathological increase in intracellular calcium, which is believed to be very toxic to the cell through its greatly increased second messenger activities.
[0008] Thus, there exists a need for a prophylaxis for the inexorable progression of brain degeneration that is a hallmark of AD, wherein the prophylaxis addresses the AR deposition, AR neurotoxicity, microglial-activated inflammation, and altered or overexpression of APP
that is seen in AD patients.
SUMMARY OF THE INVENTION
[0009] In order to meet this need, the present invention provides for the first time methods for reducing (3-amyloid deposition, (3-amyloid neurotoxicity and microgliosis in animals or humans afflicted with a cerebral amyloidogenic disease, such as Alzheimer's disease (AD), by administering therapeutically effective amounts of the dihydropyridine calcium channel antagonist, nilvadipine.
[0010] The present invention also provides methods for diagnosing cerebral amyloidogenic diseases, such has AD, in an animal or human, or determining if the animal or human is at risk for developing cerebral amyloidogenic disease, by taking a first measurement of the plasma concentration of (3-amyloid in the peripheral circulation of the animal or human;
administering a therapeutically effective amount of nilvadipine in unit dosage form to the animal or human; taking a second measurement of the plasma concentration of (3-amyloid in the peripheral circulation of the animal or human at a later time; and calculating the difference between the first measurement and the second measurement of the plasma concentration of A(3. An increase in the plasma concentration of (3-amyloid in the second measurement compared to the first measurement indicates a risk of developing and/or a possible diagnosis of a cerebral amyloidogenic disease in the animal or human.
[0011] The present invention further provides methods for reducing the risk of (3-amyloid deposition, (3-amyloid neurotoxicity and microgliosis in animals or humans suffering from traumatic brain injury by administering to the animal or human a therapeutically effective amount of nilvadipine in unit dosage form immediately after the head injury and continuing nilvadipine treatment for a prescribed period of time thereafter.
[0012] The present invention also provides methods for treating transplantable neuronal stem cells, comprising administering a therapeutically effective amount of nilvadipine to the neuronal stem cells prior to transplantation of the stem cells in the central nervous system of an animal or human afflicted with a cerebral amyloidogenic disease, such as AD.
BRIEF DESCRIPTION OF THE DRAWINGS
[0013] Fig. 1 is a bar graph that illustrates the effect of chronic administration of nilvadipine on A[3 deposition (A13 burden) in different regions of the brain of TgAPPsW mice using a 4G8 immunostaining technique;
[0014] Fig. 2 is a bar graph that illustrates the effect of chronic administration of nilvadipine on microglial activation in TgAPPsW mice in three regions of the brain using a CD45 immunostaining technique that determines the number of CD45+ microglia;
[0015] Fig. 3 is a bar graph that illustrates the effect of nilvadipine on microglial activation in N9 murine microglial cells in vitro activated with lipopolysaccharide (LPS) for 24 hours.
Microglial activation is determined by TNF-a production (pg/ml) measured by ELISA;
[0016] Fig. 4 is a bar graph that illustrates the effect of nilvadipine administration on A(3 neurotoxicity using HPNC cells treated for three days with 30 gM of pre-aggregated A[31-40 (AgA(3). Neurotoxicity is assessed by measuring the amount of lactic dehydrogenase (LDH) released from cells;
[0017] Fig. 5 is a bar graph that illustrates the effect of nilvadipine on APP
processing using human glioblastoma cells transfected with APPSW. Cells were treated with 50 n1\4 and 250 nM nilvadipine for 24 hours (fig. 5A) and for 48 hours (Fig. 5B).
Production of A[31-40 in the culture medium was measured by ELISA.
[0018] Fig. 6 is a bar graph that illustrates the effect of nilvadipine on plasma A[3 levels in two-year old TgPS/APP8W mice. Animals were treated intraperitoneally every day for three and a half weeks with nilvadipine (1.5 mg/kg of body weight).
DESCRIPTION OF THE PREFERRED EMBODIMENTS
[0019] The present invention provides for the first time prophylactic methods for the inexorable progression of brain degeneration that is a hallmark of certain cerebral amyloidogenic diseases, such as, Alzheimer's disease (AD), in animals and humans, by administering nilvadipine (isopropyl-3-methyl-2-cyano-1,4-dihydro-6-methyl-4-(m-nitrophenyl)-3,5-pyridine-dicarboxylate; MW 385.4), a dihydropyridine analogue calcium channel antagonist.
[0020] In particular, one embodiment of the present invention provides a method for reducing P-amyloid deposition, P-amyloid neurotoxicity and microgliosis in animals or humans afflicted with a cerebral amyloidogenic disease or condition by administering therapeutically effective amounts of nilvadipine in unit dosage form. Because most cerebral amyloidogenic diseases, such as AD, are chronic, progressive, intractable brain dementias, it is contemplated that the duration of nilvadipine treatment will last for up to the lifetime of the animal or human. The cerebral amyloidogenic diseases or conditions include without limitation Alzheimer's disease, transmissible spongiform encephalopathy, scrapie, traumatic brain injury, cerebral amyloid angiopathy, and Gerstmann-Straussler-Scheinker syndrome.
[0021] In another embodiment of the present invention, a method is provided for reducing the risk of (3-amyloid deposition, (3-amyloid neurotoxicity and microgliosis in animals or humans suffering from traumatic brain injury (TBI) by administering to the animal or human a therapeutically effective amount of nilvadipine in unit dosage form immediately after the TBI and continuing the nilvadipine treatment for a prescribed period of time thereafter. It has been shown TBI increases the susceptibility to the development of AD, and thus it is believed, without being bound by the theory, that TBI accelerates brain A[3 accumulation and oxidative stress, which may work synergistically to promote the onset or drive the progression of AD.
[0022] The duration of nilvadipine treatment that is contemplated for those animals or humans suffering from a TBI can last for between about one hour to five years, preferably between about two weeks to three years, and most preferably between about six months and twelve months.
[0023] In a further embodiment of the present invention, a method is provided for diagnosing or determining the risk for developing a cerebral amyloidogenic diseases, such has AD, in an animal or human, by taking a first measurement of the plasma concentration of (3-amyloid in the peripheral circulation of the animal or human; administering a therapeutically effective amount of nilvadipine in unit dosage form to the animal or human;
taking a second measurement of the plasma concentration of (3-ainyloid in the peripheral circulation of the animal or human at a later time; and then calculating the difference between the first measurement and the second measurement. An increase in the plasma concentration of P-amyloid in the second measurement compared to the first measurement indicates a risk of developing or a possible diagnosis of a cerebral amyloidogenic disease in the animal or human. The duration of time that nilvadipine is administered between the first and the second plasma A(3 concentration measurements can last for between about one day to twelve months, preferably between about one week to six months, and most preferably between about two weeks to four weeks. It is contemplated that a small increase in plasma A[3 concentration after nilvadipine administration would be indicative of a risk of developing AD
and/or diagnostic of the beginning stages of AD. Larger increases in plasma A(3 concentration after nilvadipine administration would reflect higher concentrations of A[3 liberated from the brain into the peripheral circulation and thus would be more indicative of a positive diagnosis of AD.
[0024] The therapeutically effective amount of nilvadipine that is administered in unit dosage form to animals or humans afflicted with a cerebral amyloidogenic disease or suffering from a traumatic brain injury, as well as administered for the purpose of determining the risk of developing and/or a diagnosis of a cerebral amyloidogenic disease in an animal or human, according to the methods of the present invention, can range from between about 0.05 mg to 20 mg per day, preferably from between about 2 mg to 15 mg per day, more preferably from between about 4 mg to 12 mg per day, and most preferably about 8 mg per day. The daily dosage can be administered in a single unit dose or divided into two, three or four unit doses per day.
[0025] In still another embodiment of the present invention is a method for pre-treating transplantable human or xenogenic neuronal stem cells by administering a therapeutically effective amount of nilvadipine to the neuronal stem cells prior to transplantation of the cells in the central nervous system of an animal or human that may be afflicted with a cerebral amyloidogenic disease, such as AD. Presumably, neuronal stem cells themselves would not have a significant deposition of A[3. However, if the neuronal transplant is intended for an A(3-burdened environment, pre-treatment of the neuronal stem cells should enhance the ability of the transplanted neurons to survive in their new environment by reducing the A(3 concentration and thus the A(3 toxicity therein. The therapeutically effective amount of nilvadipine that is administered in unit dosage form for pre-treating the neuronal stem cells can range from between about 1 nM to 3 M, preferably between about 10 nM to 2 M, and most preferably between about 100 nM to 1 M. It is known that stem cells, when directed to differentiate into specific cell types, such as neuronal cells, offer the possibility of a renewable source of replacement cells and tissues to treat diseases and conditions, such Alzheimer's disease, Parkinson's disease or spinal cord injury. When such cells are transplanted/implanted into a patient, it is advisable not only to pre-treat the cells with nilvadipine but to begin therapeutic treatment of the patient with nilvadipine post-implantation as well.
[0026] It is contemplated that ` the methods of the present invention may be used on transgenic animal models for AD, such as the PDAPP and TgAPPsw mouse models, which may be eventually useful for treating, preventing and/or inhibiting conditions associated with amyloid deposition, (3-amyloid neurotoxicity and microgliosis in the central nervous system of such animals or in humans. Thus, the present invention provides for transgenic animal models for AD which are constructed using standard methods known in the art and as set forth in United States Patent Nos. 5,487,992; 5,464,764; 5,387,742; 5,360,735;
BACKGROUND OF THE INVENTION
Field of the Invention [00011 'fie present invention relates to a method for treating the pathophysiological effects of cerebral amyloidogenic diseases, such as Alzheimer's disease. More specifically, the method involves administering a specific dihydropyridine antagonist calcium channel blocker, nilvadipine, which opposes such pathophysiological effects in the brain of animals or humans afflicted with diseases associated with cerebral amyloidosis, such as Alzheimer's disease.
Description of Related Art [0002] Alzheimer's disease (AD) is the most common neurodegenerative disorder of aging, afflicting approximately 1% of the population over the age of 65.
Characteristic features of the disease include the progressive accumulation of intracellular neurofibrillary tangles, extracellular parenchymal senile plaques, and cerebrovascular deposits in the brain.
The principal component of senile plaques and cerebrovascular deposits is the 39-43 amino acid (3-amyloid peptide (AR), which is proteolytically derived from amyloid precursor protein (APP), a transmembrane glycoprotein.
100031 APP is a single-transmembrane protein with a 590-680 amino acid extracellular amino terminal domain and an approximately 55 amino acid cytoplasmic tail.
Messenger RNA from the APP gene on chromosome 21 undergoes alternative splicing to yield eight possible isoforms, three of which (the 695, 751 and 770 amino acid isoforms) predominate in the brain. APP undergoes proteolytic processing via three enzymatic activities, termed a-, 0-and y-secretase. Alpha secretase cleaves APP at amino. acid 17 of the AD
domain, thus releasing the large soluble amino-terminal fragment a-APP for secretion.
Because a-secretase cleaves within the AD domain, this cleavage precludes A(3 formation.
Alternatively, APP can be cleaved by (3-secretase to define the amino terminus of A(3 and to generate the soluble amino-terminal fragment (3-APP. Subsequent cleavage of the intracellular carboxy-terminal domain of APP by y-secretase results in the generation of multiple peptides, the two most common being 40-amino acid A(3 (A(340) and 42-amino acid A(3 (A1342).
comprises 90-95% of the secreted A(3 and is the predominant species recovered from cerebrospinal fluid (Seubert et at., Nature, 359:325-7, 1992). In contrast, less than 10% of secreted A(3 is A(342. Despite the relative paucity of AR42 production, A(342 is the predominant species found in plaques and is deposited initially, perhaps due to its ability to form insoluble amyloid aggregates more rapidly than A(340 (Jarrett et al., Biochemistry, 32:4693-7, 1993). The abnormal accumulation of A[3 in the brain is believed due to either over-expression or altered processing of APP.
[0004] A(3 peptides are thus believed to play a critical role in the pathobiology of AD, as all the mutations associated with the familial form of AD result in altered processing of these peptides from APP. Indeed, deposits of insoluble, or aggregated, fibrils of A(3 in the brain are a prominent neuropathological feature of all forms of AD, regardless of the genetic predisposition of the subject.
[0005] Concomitant with A[3 deposition, there exists robust activation of inflammatory pathways in AD brain, including production of pro-inflammatory cytokines and acute-phase reactants in and around A[3 deposits (McGeer et al., J. Leukocyte Biol., 65:409-15, 1999).
Activation of the brain's resident innate immune cells, the microglia, is thought to be intimately involved in this inflammatory cascade. It has been demonstrated that reactive microglia produce pro-inflammatory cytokines, such as inflammatory proteins and acute phase reactants, such as alpha-1-antichymotrypsin, transforming growth factor (3, apolipoprotein E and complement factors, all of which have been shown to be localized to A(3 plaques and to promote A(3 plaque "condensation" or maturation (Nilsson et al., J Neurosci.
21:1444-5, 2001), and which at high levels promote neurodegeneration.
Epidemiological studies have shown that patients using non-steroidal anti-inflammatory drugs (NSAIDS) have as much as a 50% reduced risk for AD (Rogers et al., Neurobiol. Aging 17:681-6, 1996), and post-mortem evaluation of AD patients who underwent NSAID treatment has demonstrated that risk reduction is associated with diminished numbers of activated microglia (Mackenzie et al., Neurology 50:986-90, 1998). Further, when Tg APPSW mice, a mouse model for Alzheimer's disease, are given an NSAID (ibuprofen), these animals show reduction in A(3 deposits, astrocytosis, and dystrophic neurites correlating with decreased microglial activation (Lim et al., J. Neurosci. 20:5709-14, 2000).
[0006] Products of the inflammatory process in the AD brain therefore may exacerbate AD
pathology. Furthermore, there is evidence that activated microglia in AD
brain, instead of clearing A(3, are pathogenic by promoting A(3 fibrillogenesis and consequent deposition as senile plaques (Wegiel et al., Acta Neuropathol. (Berl.) 100:356-64, 2000).
[0007] It also has been suggested that AD pathogenesis is due to the neurotoxic properties of AR. The cytotoxicity of A13 was first established in primary cell cultures from rodent brains and also in human cell cultures. The work of Mattson et al. (J.
Neurosci., 12:376-389, 1992) indicates that A(3, in the presence of the excitatory neurotransmitter glutamate, causes an immediate pathological increase in intracellular calcium, which is believed to be very toxic to the cell through its greatly increased second messenger activities.
[0008] Thus, there exists a need for a prophylaxis for the inexorable progression of brain degeneration that is a hallmark of AD, wherein the prophylaxis addresses the AR deposition, AR neurotoxicity, microglial-activated inflammation, and altered or overexpression of APP
that is seen in AD patients.
SUMMARY OF THE INVENTION
[0009] In order to meet this need, the present invention provides for the first time methods for reducing (3-amyloid deposition, (3-amyloid neurotoxicity and microgliosis in animals or humans afflicted with a cerebral amyloidogenic disease, such as Alzheimer's disease (AD), by administering therapeutically effective amounts of the dihydropyridine calcium channel antagonist, nilvadipine.
[0010] The present invention also provides methods for diagnosing cerebral amyloidogenic diseases, such has AD, in an animal or human, or determining if the animal or human is at risk for developing cerebral amyloidogenic disease, by taking a first measurement of the plasma concentration of (3-amyloid in the peripheral circulation of the animal or human;
administering a therapeutically effective amount of nilvadipine in unit dosage form to the animal or human; taking a second measurement of the plasma concentration of (3-amyloid in the peripheral circulation of the animal or human at a later time; and calculating the difference between the first measurement and the second measurement of the plasma concentration of A(3. An increase in the plasma concentration of (3-amyloid in the second measurement compared to the first measurement indicates a risk of developing and/or a possible diagnosis of a cerebral amyloidogenic disease in the animal or human.
[0011] The present invention further provides methods for reducing the risk of (3-amyloid deposition, (3-amyloid neurotoxicity and microgliosis in animals or humans suffering from traumatic brain injury by administering to the animal or human a therapeutically effective amount of nilvadipine in unit dosage form immediately after the head injury and continuing nilvadipine treatment for a prescribed period of time thereafter.
[0012] The present invention also provides methods for treating transplantable neuronal stem cells, comprising administering a therapeutically effective amount of nilvadipine to the neuronal stem cells prior to transplantation of the stem cells in the central nervous system of an animal or human afflicted with a cerebral amyloidogenic disease, such as AD.
BRIEF DESCRIPTION OF THE DRAWINGS
[0013] Fig. 1 is a bar graph that illustrates the effect of chronic administration of nilvadipine on A[3 deposition (A13 burden) in different regions of the brain of TgAPPsW mice using a 4G8 immunostaining technique;
[0014] Fig. 2 is a bar graph that illustrates the effect of chronic administration of nilvadipine on microglial activation in TgAPPsW mice in three regions of the brain using a CD45 immunostaining technique that determines the number of CD45+ microglia;
[0015] Fig. 3 is a bar graph that illustrates the effect of nilvadipine on microglial activation in N9 murine microglial cells in vitro activated with lipopolysaccharide (LPS) for 24 hours.
Microglial activation is determined by TNF-a production (pg/ml) measured by ELISA;
[0016] Fig. 4 is a bar graph that illustrates the effect of nilvadipine administration on A(3 neurotoxicity using HPNC cells treated for three days with 30 gM of pre-aggregated A[31-40 (AgA(3). Neurotoxicity is assessed by measuring the amount of lactic dehydrogenase (LDH) released from cells;
[0017] Fig. 5 is a bar graph that illustrates the effect of nilvadipine on APP
processing using human glioblastoma cells transfected with APPSW. Cells were treated with 50 n1\4 and 250 nM nilvadipine for 24 hours (fig. 5A) and for 48 hours (Fig. 5B).
Production of A[31-40 in the culture medium was measured by ELISA.
[0018] Fig. 6 is a bar graph that illustrates the effect of nilvadipine on plasma A[3 levels in two-year old TgPS/APP8W mice. Animals were treated intraperitoneally every day for three and a half weeks with nilvadipine (1.5 mg/kg of body weight).
DESCRIPTION OF THE PREFERRED EMBODIMENTS
[0019] The present invention provides for the first time prophylactic methods for the inexorable progression of brain degeneration that is a hallmark of certain cerebral amyloidogenic diseases, such as, Alzheimer's disease (AD), in animals and humans, by administering nilvadipine (isopropyl-3-methyl-2-cyano-1,4-dihydro-6-methyl-4-(m-nitrophenyl)-3,5-pyridine-dicarboxylate; MW 385.4), a dihydropyridine analogue calcium channel antagonist.
[0020] In particular, one embodiment of the present invention provides a method for reducing P-amyloid deposition, P-amyloid neurotoxicity and microgliosis in animals or humans afflicted with a cerebral amyloidogenic disease or condition by administering therapeutically effective amounts of nilvadipine in unit dosage form. Because most cerebral amyloidogenic diseases, such as AD, are chronic, progressive, intractable brain dementias, it is contemplated that the duration of nilvadipine treatment will last for up to the lifetime of the animal or human. The cerebral amyloidogenic diseases or conditions include without limitation Alzheimer's disease, transmissible spongiform encephalopathy, scrapie, traumatic brain injury, cerebral amyloid angiopathy, and Gerstmann-Straussler-Scheinker syndrome.
[0021] In another embodiment of the present invention, a method is provided for reducing the risk of (3-amyloid deposition, (3-amyloid neurotoxicity and microgliosis in animals or humans suffering from traumatic brain injury (TBI) by administering to the animal or human a therapeutically effective amount of nilvadipine in unit dosage form immediately after the TBI and continuing the nilvadipine treatment for a prescribed period of time thereafter. It has been shown TBI increases the susceptibility to the development of AD, and thus it is believed, without being bound by the theory, that TBI accelerates brain A[3 accumulation and oxidative stress, which may work synergistically to promote the onset or drive the progression of AD.
[0022] The duration of nilvadipine treatment that is contemplated for those animals or humans suffering from a TBI can last for between about one hour to five years, preferably between about two weeks to three years, and most preferably between about six months and twelve months.
[0023] In a further embodiment of the present invention, a method is provided for diagnosing or determining the risk for developing a cerebral amyloidogenic diseases, such has AD, in an animal or human, by taking a first measurement of the plasma concentration of (3-amyloid in the peripheral circulation of the animal or human; administering a therapeutically effective amount of nilvadipine in unit dosage form to the animal or human;
taking a second measurement of the plasma concentration of (3-ainyloid in the peripheral circulation of the animal or human at a later time; and then calculating the difference between the first measurement and the second measurement. An increase in the plasma concentration of P-amyloid in the second measurement compared to the first measurement indicates a risk of developing or a possible diagnosis of a cerebral amyloidogenic disease in the animal or human. The duration of time that nilvadipine is administered between the first and the second plasma A(3 concentration measurements can last for between about one day to twelve months, preferably between about one week to six months, and most preferably between about two weeks to four weeks. It is contemplated that a small increase in plasma A[3 concentration after nilvadipine administration would be indicative of a risk of developing AD
and/or diagnostic of the beginning stages of AD. Larger increases in plasma A(3 concentration after nilvadipine administration would reflect higher concentrations of A[3 liberated from the brain into the peripheral circulation and thus would be more indicative of a positive diagnosis of AD.
[0024] The therapeutically effective amount of nilvadipine that is administered in unit dosage form to animals or humans afflicted with a cerebral amyloidogenic disease or suffering from a traumatic brain injury, as well as administered for the purpose of determining the risk of developing and/or a diagnosis of a cerebral amyloidogenic disease in an animal or human, according to the methods of the present invention, can range from between about 0.05 mg to 20 mg per day, preferably from between about 2 mg to 15 mg per day, more preferably from between about 4 mg to 12 mg per day, and most preferably about 8 mg per day. The daily dosage can be administered in a single unit dose or divided into two, three or four unit doses per day.
[0025] In still another embodiment of the present invention is a method for pre-treating transplantable human or xenogenic neuronal stem cells by administering a therapeutically effective amount of nilvadipine to the neuronal stem cells prior to transplantation of the cells in the central nervous system of an animal or human that may be afflicted with a cerebral amyloidogenic disease, such as AD. Presumably, neuronal stem cells themselves would not have a significant deposition of A[3. However, if the neuronal transplant is intended for an A(3-burdened environment, pre-treatment of the neuronal stem cells should enhance the ability of the transplanted neurons to survive in their new environment by reducing the A(3 concentration and thus the A(3 toxicity therein. The therapeutically effective amount of nilvadipine that is administered in unit dosage form for pre-treating the neuronal stem cells can range from between about 1 nM to 3 M, preferably between about 10 nM to 2 M, and most preferably between about 100 nM to 1 M. It is known that stem cells, when directed to differentiate into specific cell types, such as neuronal cells, offer the possibility of a renewable source of replacement cells and tissues to treat diseases and conditions, such Alzheimer's disease, Parkinson's disease or spinal cord injury. When such cells are transplanted/implanted into a patient, it is advisable not only to pre-treat the cells with nilvadipine but to begin therapeutic treatment of the patient with nilvadipine post-implantation as well.
[0026] It is contemplated that ` the methods of the present invention may be used on transgenic animal models for AD, such as the PDAPP and TgAPPsw mouse models, which may be eventually useful for treating, preventing and/or inhibiting conditions associated with amyloid deposition, (3-amyloid neurotoxicity and microgliosis in the central nervous system of such animals or in humans. Thus, the present invention provides for transgenic animal models for AD which are constructed using standard methods known in the art and as set forth in United States Patent Nos. 5,487,992; 5,464,764; 5,387,742; 5,360,735;
5,347,075;
5,298,422; 5,288,846; 5,221,778; 5,175,385; 5,175,384; 5,175,383; and 4,736,866.
[0027] Nilvadipine can be administered to a patient via various routes including parenterally, orally or intraperitoneally. Parenteral administration includes the following routes: intravenous; intramuscular; interstitial; intra-arterial;
subcutaneous; intraocular;
intracranial; intraventricular; ~ intrasynovial; transepithelial, including transdermal, pulmonary via inhalation, ophthalmic, sublingual and buccal; topical, including ophthalmic, dermal, ocular, rectal, or nasal inhalation via insufflation or nebulization.
[0028] Nilvadipine that is orally administered can be enclosed in hard or soft shell gelatin capsules, or compressed into tablets. Nilvadipine also can be incorporated with an excipient and used in the form of ingestible tablets, buccal tablets, troches, capsules, sachets, lozenges, elixirs, suspensions, syrups, wafers, and the like. Further, nilvadipine can be in the form of a powder or granule, a solution or suspension in an aqueous liquid or non-aqueous liquid, or in an oil-in-water or water-in-oil emulsion.
[0029] The tablets, troches, pills, capsules and the like also can contain, for example, a binder, such as gum tragacanth, acacia, corn starch; gelating excipients, such as dicalcium phosphate; a disintegrating agent, such as corn starch, potato starch, alginic acid and the like;
a lubricant, such as magnesium stearate; a sweetening agent, such as sucrose, lactose or saccharin; or a flavoring agent. When the dosage unit form is a capsule, it can contain, in addition to the materials described above, a liquid carrier. Various other materials can be present as coatings or to otherwise modify the physical form of the dosage unit. For example, tablets, pills, or capsules can be coated with shellac, sugar or both. A syrup or elixir can contain nilvadipine, sucrose as a sweetening agent, methyl and propylparabens as preservatives, a dye and flavoring. Additionally, nilvadipine can be incorporated into sustained-release preparations and formulations.
[0030] Nilvadipine can be administered to the CNS, parenterally or intraperitoneally.
Solutions of nilvadipine as a free base or a pharmaceutically acceptable salt can be prepared in water mixed with a suitable surfactant, such as hydroxypropylcellulose.
Dispersions also can be prepared in glycerol, liquid polyethylene glycols, and mixtures thereof, and in oils.
Under ordinary conditions of storage and use, these preparations can contain a preservative and/or antioxidants to prevent the growth of microorganisms or chemical degeneration.
[0031] The methods of the present invention for reducing the pathological effects of A(3 in animals or humans suffering from diseases associated with amyloidosis, such as AD, will be described in more detail in the following non-limiting examples.
Example 1-Chronic Administration of Nilvadipine on Aj3 deposition (Amyloid Burden) [0032] The effect of chronic administration of nilvadipine on A(3 deposition (amyloid burden) in different regions of the brain of TgAPPsw mice was examined using a 4G8 anti-A(3 monoclonal antibody immunostaining technique. The 4G8 immunostaining technique was chosen for determining the A!3 burden because of its robust signal and optimal results for quantitative analysis of A!3 deposition. Briefly, paraffin sections were subjected to immunohistochemistry as described previously (Nakagawa, Y et al., Exp.
Neurol., 163:244-252, 2000). Sections were deparaffinized in xylene, hydrated in a series of ethanol and deionized water, and subjected to an antigen retrieval step by immersing sections in 88%
formic acid for 60 min before immunohistochemistry for A(3. Sections were washed in water, and endogenous peroxidases were quenched using a freshly prepared mixture of methanol, (150 ml) plus hydrogen peroxide (33%, 30 ml). The avidin-biotin complex method was used according to the instructions of the vendor (Vector Laboratories, Burlingame, CA). Amyloid burden was assessed by determining the percentage of the brain region that stained positive for A. Negative controls included the application of the same immunohistochemistry protocol to sections, except preimmune serum was applied instead of primary antibody.
TgAPPsw mice were divided into an experimental group that received an effective amount of nilvadipine (n=7) and a control group that received a vehicle (n=5).
[0033] As shown in Fig. 1, treatment with nilvadipine reduced the AR burden about 62% in the visual cortex compared to controls, about 65% in the parietal cortex compared to controls, about 58% in the motor cortex compared to controls, about 58% in the pyriform cortex compared to controls, about 52% in the CAl region of the hippocampus compared to controls, and about 50% in the CA2-CA3 region of the hippocampus compared to controls.
Example 2- Chronic Administration of Nilvadipine on Microglial Activation [0034] The effect of chronic administration of nilvadipine on microglial activation in TgAPPsw mice was examined in three regions of the mouse brain using a CD45 immunostaining technique in which the number of CD45 + microglia was determined.
[0035] Briefly, immunohistochemistry for CD45, a specific marker for leukocytes, was conducted on the cryostat brain sections. CD45-positive microglial cells were immunolocalized by incubation with a mouse monoclonal antibody against CD45 (Chemicon International) overnight at 4 C, followed by application of a biotinylated rabbit anti-mouse secondary antibody for 30 minutes. Detection of CD45 was completed with diaminobenzidine chromogen substrate, which produces a brown cell surface stain on CD45-positive microglial cells.
[0036] As shown in Fig. 2, nilvadipine treatment administered in an effective dosage amount reduced microglial activation about 33% in the hippocampus, about 43%
in the parietal cortex, and about 27% in the motor cortex, when compared to controls.
Example 3- The Effect of Nilvadipine Administration on Microglial Activation [0037] The effect of nilvadipine on microglial activation was examined in N9 murine microglial cells in vitro activated with lipopolysaccharide (LPS) for 24 hours. N9 murine micoglial cells are well characterized scavenger murine microglial clones derived from embryonic mouse brain. The extent of microglial activation was determined by TNF-a production (pg/ml) measured by ELISA. As shown in Fig. 3, microglial cells not activated with LPS (control cells) produced about 40 pg/ml TNF-a. Microglial cells in the presence of 50 nM nilvadipine produced about 40 pg/ml TNF-a. Increasing nilvadipine administration 10-fold (500 nM) did not change TNF-a production. Microglial cells in the presence of 1 g/ml LPS produced about 820 pg/ml TNF-a, an increase of about 95% from the control cells and nilvadipine-administered cells. Microglial cells in the presence of both 1 gg/ml LPS
plus 50 nM nilvadipine produced about 670 pg/ml TNF-a. LPS plus 500 nM
nilvadipine administration decreased TNF-a production to about 610 pg/ml. Thus, nilvadipine opposed the LPS-induced microglial activation by about 20 to 25%.
Example 4- The Effect of Nilvadipine Administration on A(3 Neurotoxicity [0038] The effect of nilvadipine administration (10 nM and 100 nM) on A(3 neurotoxicity was examined using human neuronal progenitor cells (HNPC) treated for three days with 30 M of pre-aggregated A(31-40 (AgA(3). HNPC cells differentiate into neurons readily upon treatment with cyclic AMP. Cyclic AMP (1 mm) (Sigma) was added to the culture medium and the HNPC cells were incubated at 37 C for 48 hours or more under serum free conditions. This medium allowed differentiation of the progenitors into cells of neuronal lineage, as was confirmed by the staining of most of the cells with antibodies against the microtubule-associated protein, MAP-2. Neurotoxicity was assessed by measuring the amount of lactic dehydrogenase (LDH; an intracellular enzyme found in all cells) released from the cells.
[0039] As shown in Fig. 4, treatment of the cells with AgA(3 produced about a 44%
increase in LDH release compared to treatment of the cells with nilvadipine.
There was no change in LDH release when 10 nM nilvadipine was added along with AgA(3.
However, when the dosage amount of nilvadipine was increased 10-fold to 100 nM, the amount of LDH
release was decreased by about 44%.
Example 5- The Effect of Nilvadipine Administration on APP Processing [0040] The effect of nilvadipine on APP processing was examined using human glioblastoma cells transfected with APPsw. The cells were treated with-50 n1\4 and 250 rLM
nilvadipine for 24 and 48 hours, and production of A131-40 in the culture medium was measured by using a commercially available human AR 1-40 ELISA (Biosource, CA).
[0041] As shown in Fig. 5A, after 24 hours of treatment, 50 nM of nilvadipine reduced the production of A131-40 by about 9%, and 250 nM of nilvadipine reduced A[31-40 production by about 15%. After 48 hours of treatment (Fig. 5B), 50 nM of nilvadipine reduced the production of A(31-40 by about 18%, and 250 nM of nilvadipine reduced A(31-40 production by about 5%.
Example 6- Effect of Nilvadipine Administration on Plasma A(3 Levels [0042] The effect of nilvadipine administration on plasma A(3 levels (pg/ml) was examined using 2 year old TgPS/APPsw mice. Animals were treated intraperitoneally (I.P.) every day for three and one half weeks with nilvadipine (1.5 mg/kg of body weight; n =
10) or vehicle only (50% DMSO in PBS; n = 12). Following this treatment, 100 l of blood were collected from the tail vein of the animals using EDTA (4%) as an anticoagulant. Blood samples were centrifuged at 4000 g for 1 min and the plasma was collected and diluted four times before being assayed for human A[3l-40 using a commercially available human A!31-40 ELISA
(Biosource, CA).
[0043] As shown in Fig. 6, I.P. administration of nilvadipine to TgPS/APPsw mice at a dose of 1.5 mg/kg body weight for three and one half weeks resulted in a 42%
increase in the plasma levels of A[3 (pg/ml) compared to the control animals.
General Conclusions [0044] Chronic administration of nilvadipine significantly reduced the amount of AP
present in different regions of the cerebral cortex and hippocampus of transgenic mice, as well as significantly reducing the degree of microglial activation. When N9 murine microglial cells were activated with LPS, nilvadipine administration significantly reduced LPS-induced microglial activation. Furthermore, nilvadipine effectively opposed the neurotoxic effect of AgA[3 on a human precursor neuronal cell line. Although the production of A[31-40 was not significantly decreased by nilvadipine treatment, there was a trend toward decreased A(31-40 production after nilvadipine administration. This reduction in A131-40 potentially reflects reduced production, but other mechanisms to which the lowered appearance of A(31-40 might be attributable would include, without limitation, phagocytosis or other destruction, or cellular effects which prevent its aggregation and detection.
Regardless of the mechanism, however, the data suggest that the presence of nilvadipine concomitantly reduced the presence of A(31-40. Finally, chronic administration of nilvadipine I.P. to 2-year old TgPS/APPsw mice significantly increased the plasma levels of A(3, suggesting that, in addition to the ability of nilvadipine to reduce deposition of A(3 in the brain, nilvadipine treatment may reduce A(3 that already is already deposited in the brains of afflicted subjects.
[0045] In view of the above data, it can be extrapolated that nilvadipine administration to animals or humans afflicted with a cerebral amyloidogenic disease, such as AD, can significantly decrease the amount of A[3 deposition in critical regions of the brain that characteristically demonstrate an abundance of such pathological deposits as well as reduce the amount of A(3 already deposited in the brain. Additionally, nilvadipine administration may oppose the neurotoxic effects of A[3, effects which are believed to be responsible for the widespread and devastating neuronal destruction seen with AD, as well as reduce microglial activation that causes the characteristic inflammatory response seen in the brains of AD
patients. Finally, nilvadipine treatment may reduce the concentration of already deposited A(3 in brains of animals or humans afflicted with cerebral amyloidogenic diseases such as AD.
[0046] It will be apparent to those skilled in the art that various modifications and variations can be made in the methods of the present invention without departing from the spirit or scope of the invention. Thus, it is intended that the present invention include modifications and variations that are within the scope of the appended claims and their equivalents.
5,298,422; 5,288,846; 5,221,778; 5,175,385; 5,175,384; 5,175,383; and 4,736,866.
[0027] Nilvadipine can be administered to a patient via various routes including parenterally, orally or intraperitoneally. Parenteral administration includes the following routes: intravenous; intramuscular; interstitial; intra-arterial;
subcutaneous; intraocular;
intracranial; intraventricular; ~ intrasynovial; transepithelial, including transdermal, pulmonary via inhalation, ophthalmic, sublingual and buccal; topical, including ophthalmic, dermal, ocular, rectal, or nasal inhalation via insufflation or nebulization.
[0028] Nilvadipine that is orally administered can be enclosed in hard or soft shell gelatin capsules, or compressed into tablets. Nilvadipine also can be incorporated with an excipient and used in the form of ingestible tablets, buccal tablets, troches, capsules, sachets, lozenges, elixirs, suspensions, syrups, wafers, and the like. Further, nilvadipine can be in the form of a powder or granule, a solution or suspension in an aqueous liquid or non-aqueous liquid, or in an oil-in-water or water-in-oil emulsion.
[0029] The tablets, troches, pills, capsules and the like also can contain, for example, a binder, such as gum tragacanth, acacia, corn starch; gelating excipients, such as dicalcium phosphate; a disintegrating agent, such as corn starch, potato starch, alginic acid and the like;
a lubricant, such as magnesium stearate; a sweetening agent, such as sucrose, lactose or saccharin; or a flavoring agent. When the dosage unit form is a capsule, it can contain, in addition to the materials described above, a liquid carrier. Various other materials can be present as coatings or to otherwise modify the physical form of the dosage unit. For example, tablets, pills, or capsules can be coated with shellac, sugar or both. A syrup or elixir can contain nilvadipine, sucrose as a sweetening agent, methyl and propylparabens as preservatives, a dye and flavoring. Additionally, nilvadipine can be incorporated into sustained-release preparations and formulations.
[0030] Nilvadipine can be administered to the CNS, parenterally or intraperitoneally.
Solutions of nilvadipine as a free base or a pharmaceutically acceptable salt can be prepared in water mixed with a suitable surfactant, such as hydroxypropylcellulose.
Dispersions also can be prepared in glycerol, liquid polyethylene glycols, and mixtures thereof, and in oils.
Under ordinary conditions of storage and use, these preparations can contain a preservative and/or antioxidants to prevent the growth of microorganisms or chemical degeneration.
[0031] The methods of the present invention for reducing the pathological effects of A(3 in animals or humans suffering from diseases associated with amyloidosis, such as AD, will be described in more detail in the following non-limiting examples.
Example 1-Chronic Administration of Nilvadipine on Aj3 deposition (Amyloid Burden) [0032] The effect of chronic administration of nilvadipine on A(3 deposition (amyloid burden) in different regions of the brain of TgAPPsw mice was examined using a 4G8 anti-A(3 monoclonal antibody immunostaining technique. The 4G8 immunostaining technique was chosen for determining the A!3 burden because of its robust signal and optimal results for quantitative analysis of A!3 deposition. Briefly, paraffin sections were subjected to immunohistochemistry as described previously (Nakagawa, Y et al., Exp.
Neurol., 163:244-252, 2000). Sections were deparaffinized in xylene, hydrated in a series of ethanol and deionized water, and subjected to an antigen retrieval step by immersing sections in 88%
formic acid for 60 min before immunohistochemistry for A(3. Sections were washed in water, and endogenous peroxidases were quenched using a freshly prepared mixture of methanol, (150 ml) plus hydrogen peroxide (33%, 30 ml). The avidin-biotin complex method was used according to the instructions of the vendor (Vector Laboratories, Burlingame, CA). Amyloid burden was assessed by determining the percentage of the brain region that stained positive for A. Negative controls included the application of the same immunohistochemistry protocol to sections, except preimmune serum was applied instead of primary antibody.
TgAPPsw mice were divided into an experimental group that received an effective amount of nilvadipine (n=7) and a control group that received a vehicle (n=5).
[0033] As shown in Fig. 1, treatment with nilvadipine reduced the AR burden about 62% in the visual cortex compared to controls, about 65% in the parietal cortex compared to controls, about 58% in the motor cortex compared to controls, about 58% in the pyriform cortex compared to controls, about 52% in the CAl region of the hippocampus compared to controls, and about 50% in the CA2-CA3 region of the hippocampus compared to controls.
Example 2- Chronic Administration of Nilvadipine on Microglial Activation [0034] The effect of chronic administration of nilvadipine on microglial activation in TgAPPsw mice was examined in three regions of the mouse brain using a CD45 immunostaining technique in which the number of CD45 + microglia was determined.
[0035] Briefly, immunohistochemistry for CD45, a specific marker for leukocytes, was conducted on the cryostat brain sections. CD45-positive microglial cells were immunolocalized by incubation with a mouse monoclonal antibody against CD45 (Chemicon International) overnight at 4 C, followed by application of a biotinylated rabbit anti-mouse secondary antibody for 30 minutes. Detection of CD45 was completed with diaminobenzidine chromogen substrate, which produces a brown cell surface stain on CD45-positive microglial cells.
[0036] As shown in Fig. 2, nilvadipine treatment administered in an effective dosage amount reduced microglial activation about 33% in the hippocampus, about 43%
in the parietal cortex, and about 27% in the motor cortex, when compared to controls.
Example 3- The Effect of Nilvadipine Administration on Microglial Activation [0037] The effect of nilvadipine on microglial activation was examined in N9 murine microglial cells in vitro activated with lipopolysaccharide (LPS) for 24 hours. N9 murine micoglial cells are well characterized scavenger murine microglial clones derived from embryonic mouse brain. The extent of microglial activation was determined by TNF-a production (pg/ml) measured by ELISA. As shown in Fig. 3, microglial cells not activated with LPS (control cells) produced about 40 pg/ml TNF-a. Microglial cells in the presence of 50 nM nilvadipine produced about 40 pg/ml TNF-a. Increasing nilvadipine administration 10-fold (500 nM) did not change TNF-a production. Microglial cells in the presence of 1 g/ml LPS produced about 820 pg/ml TNF-a, an increase of about 95% from the control cells and nilvadipine-administered cells. Microglial cells in the presence of both 1 gg/ml LPS
plus 50 nM nilvadipine produced about 670 pg/ml TNF-a. LPS plus 500 nM
nilvadipine administration decreased TNF-a production to about 610 pg/ml. Thus, nilvadipine opposed the LPS-induced microglial activation by about 20 to 25%.
Example 4- The Effect of Nilvadipine Administration on A(3 Neurotoxicity [0038] The effect of nilvadipine administration (10 nM and 100 nM) on A(3 neurotoxicity was examined using human neuronal progenitor cells (HNPC) treated for three days with 30 M of pre-aggregated A(31-40 (AgA(3). HNPC cells differentiate into neurons readily upon treatment with cyclic AMP. Cyclic AMP (1 mm) (Sigma) was added to the culture medium and the HNPC cells were incubated at 37 C for 48 hours or more under serum free conditions. This medium allowed differentiation of the progenitors into cells of neuronal lineage, as was confirmed by the staining of most of the cells with antibodies against the microtubule-associated protein, MAP-2. Neurotoxicity was assessed by measuring the amount of lactic dehydrogenase (LDH; an intracellular enzyme found in all cells) released from the cells.
[0039] As shown in Fig. 4, treatment of the cells with AgA(3 produced about a 44%
increase in LDH release compared to treatment of the cells with nilvadipine.
There was no change in LDH release when 10 nM nilvadipine was added along with AgA(3.
However, when the dosage amount of nilvadipine was increased 10-fold to 100 nM, the amount of LDH
release was decreased by about 44%.
Example 5- The Effect of Nilvadipine Administration on APP Processing [0040] The effect of nilvadipine on APP processing was examined using human glioblastoma cells transfected with APPsw. The cells were treated with-50 n1\4 and 250 rLM
nilvadipine for 24 and 48 hours, and production of A131-40 in the culture medium was measured by using a commercially available human AR 1-40 ELISA (Biosource, CA).
[0041] As shown in Fig. 5A, after 24 hours of treatment, 50 nM of nilvadipine reduced the production of A131-40 by about 9%, and 250 nM of nilvadipine reduced A[31-40 production by about 15%. After 48 hours of treatment (Fig. 5B), 50 nM of nilvadipine reduced the production of A(31-40 by about 18%, and 250 nM of nilvadipine reduced A(31-40 production by about 5%.
Example 6- Effect of Nilvadipine Administration on Plasma A(3 Levels [0042] The effect of nilvadipine administration on plasma A(3 levels (pg/ml) was examined using 2 year old TgPS/APPsw mice. Animals were treated intraperitoneally (I.P.) every day for three and one half weeks with nilvadipine (1.5 mg/kg of body weight; n =
10) or vehicle only (50% DMSO in PBS; n = 12). Following this treatment, 100 l of blood were collected from the tail vein of the animals using EDTA (4%) as an anticoagulant. Blood samples were centrifuged at 4000 g for 1 min and the plasma was collected and diluted four times before being assayed for human A[3l-40 using a commercially available human A!31-40 ELISA
(Biosource, CA).
[0043] As shown in Fig. 6, I.P. administration of nilvadipine to TgPS/APPsw mice at a dose of 1.5 mg/kg body weight for three and one half weeks resulted in a 42%
increase in the plasma levels of A[3 (pg/ml) compared to the control animals.
General Conclusions [0044] Chronic administration of nilvadipine significantly reduced the amount of AP
present in different regions of the cerebral cortex and hippocampus of transgenic mice, as well as significantly reducing the degree of microglial activation. When N9 murine microglial cells were activated with LPS, nilvadipine administration significantly reduced LPS-induced microglial activation. Furthermore, nilvadipine effectively opposed the neurotoxic effect of AgA[3 on a human precursor neuronal cell line. Although the production of A[31-40 was not significantly decreased by nilvadipine treatment, there was a trend toward decreased A(31-40 production after nilvadipine administration. This reduction in A131-40 potentially reflects reduced production, but other mechanisms to which the lowered appearance of A(31-40 might be attributable would include, without limitation, phagocytosis or other destruction, or cellular effects which prevent its aggregation and detection.
Regardless of the mechanism, however, the data suggest that the presence of nilvadipine concomitantly reduced the presence of A(31-40. Finally, chronic administration of nilvadipine I.P. to 2-year old TgPS/APPsw mice significantly increased the plasma levels of A(3, suggesting that, in addition to the ability of nilvadipine to reduce deposition of A(3 in the brain, nilvadipine treatment may reduce A(3 that already is already deposited in the brains of afflicted subjects.
[0045] In view of the above data, it can be extrapolated that nilvadipine administration to animals or humans afflicted with a cerebral amyloidogenic disease, such as AD, can significantly decrease the amount of A[3 deposition in critical regions of the brain that characteristically demonstrate an abundance of such pathological deposits as well as reduce the amount of A(3 already deposited in the brain. Additionally, nilvadipine administration may oppose the neurotoxic effects of A[3, effects which are believed to be responsible for the widespread and devastating neuronal destruction seen with AD, as well as reduce microglial activation that causes the characteristic inflammatory response seen in the brains of AD
patients. Finally, nilvadipine treatment may reduce the concentration of already deposited A(3 in brains of animals or humans afflicted with cerebral amyloidogenic diseases such as AD.
[0046] It will be apparent to those skilled in the art that various modifications and variations can be made in the methods of the present invention without departing from the spirit or scope of the invention. Thus, it is intended that the present invention include modifications and variations that are within the scope of the appended claims and their equivalents.
Claims (47)
1. Use of nilvadipine for reducing .beta.-amyloid deposition, .beta.-amyloid neuro-toxicity and microgliosis in animals and humans afflicted with a cerebral amyloidogenic disease or condition.
2. The use according to claim 1, wherein the cerebral amyloidogenic disease or condition is selected from the group consisting of Alzheimer's disease, transmissible spongi-form encephalopathy, scrapie, traumatic brain injury, cerebral amyloid angiopathy and Gerstmann-Straussler-Scheinker syndrome.
3. The use according to claim 1, wherein said use comprises use in a human of an amount of nilvadipine of 0.05-20 mg per day.
4. The use according to claim 1, wherein said use comprises use in a human of an amount of nilvadipine of 2-15 mg per day.
5. The use according to claim 1, wherein said use comprises use in a human of an amount of nilvadipine of 4-12 mg per day.
6. The use according to claim 1, wherein said use comprises use in a human of an amount of nilvadipine of about 8 mg per day.
7. The use according to claim 1, wherein said use is for the duration of the lifetime of the animal or human.
8. The use according to claim 1, wherein the use of nilvadipine is for parenteral, oral or intraperitoneal administration.
9. The use according to claim 8 for oral administration, wherein the oral administration is selected from the group consisting of hard or soft shell gelatin capsules, tablets, troches, sachets, lozenges, elixirs, suspensions, syrups, wafers, powders, granules, solutions and emulsions.
10. The use according to claim 8 for parenteral administration, wherein the parenteral administration is intravenous, intramuscular, interstitial, intra-arterial, subcutaneous, intraocular, intracranial, intraventricular, intrasynovial, transepithelial, or topical.
11. The use according to claim 8 for parenteral administration, wherein the parenteral administration is transepithelial administration that is transdermal, pulmonary via inhalation, ophthalmic, sublingual or buccal.
12. The use according to claim 8 for parenteral administration, wherein the parenteral administration is topical administration that is ophthalmic, dermal, ocular, rectal, or nasal.
13. The use according to claim 12, wherein the topical administration is nasal administration via aerosols, atomizers or nebulizers or that is nasal inhalation via insufflation.
14. A diagnostic method for a cerebral amyloidogenic disease in an animal or human, comprising:
taking a first measurement of the plasma concentration of .beta.-amyloid in a first blood sample from the peripheral circulation of the animal or human wherein said first blood sample is taken prior to use of nilvadipine to treat the animal or human;
taking a second measurement of the plasma concentration of .beta.- amyloid in a second blood sample from the peripheral circulation of the animal or human, wherein said second blood sample is taken subsequent to the use of nilvadipine to treat the animal or human; and calculating the difference between the first measurement and the second measure-ment, wherein an increase in the plasma concentration of .beta.-amyloid in the second measure-ment compared to the first measurement indicates a possible diagnosis of a cerebral amyloidogenic disease in the animal or human.
taking a first measurement of the plasma concentration of .beta.-amyloid in a first blood sample from the peripheral circulation of the animal or human wherein said first blood sample is taken prior to use of nilvadipine to treat the animal or human;
taking a second measurement of the plasma concentration of .beta.- amyloid in a second blood sample from the peripheral circulation of the animal or human, wherein said second blood sample is taken subsequent to the use of nilvadipine to treat the animal or human; and calculating the difference between the first measurement and the second measure-ment, wherein an increase in the plasma concentration of .beta.-amyloid in the second measure-ment compared to the first measurement indicates a possible diagnosis of a cerebral amyloidogenic disease in the animal or human.
15. The method of claim 14, wherein the cerebral amyloidogenic disease is selected from the group consisting of Alzheimer's disease, transmissible spongiform encephalopathy, scrapie, traumatic brain injury, cerebral amyloid angiopathy, and Gerstmann-Straussler-Scheinker syndrome.
16. The method of claim 15, wherein the use of nilvadipine is in an amount of 0.05-20 mg per day.
17. The method of claim 14, wherein the use of nilvadipine is in an amount of 15 mg per day.
18. The method of claim 14, wherein the use of nilvadipine is in an amount of 12 mg per day.
19. The method of claim 14, wherein the use of nilvadipine is in an amount of about 8 mg per day.
20. The method of claim 14, wherein the use of nilvadipine is for a duration of between one day and twelve months.
21. The method of claim 14, wherein the use of nilvadipine is for a duration of between one week and six months.
22. The method of claim 14, wherein the use of nilvadipine is for a duration of between two weeks and four weeks.
23. The method of claim 14, wherein the use of nilvadipine is for parenteral, oral or intraperitoneal administration.
24. The method of claim 23, wherein the oral administration is selected from the group consisting of hard or soft shell gelatin capsules, tablets, troches, sachets, lozenges, elixirs, suspensions, syrups, wafers, powders, granules, solutions and emulsions.
25. The method of claim 23, wherein said use is for parenteral administration and said parenteral administration is intravenous, intramuscular, interstitial, intra-arterial, sub-cutaneous, intraocular, intracranial, intraventricular, intrasynovial, transepithelial, or topical.
26. The method according to claim 23 where said use is for parenteral administration, wherein the parenteral administration is transepithelial administration that is transdermal, pulmonary via inhalation, ophthalmic, sublingual or buccal.
27. The method according to claim 23 wherein said use is for parenteral admini-stration, wherein the parenteral administration is topical administration that is ophthalmic, dermal, ocular, rectal, or nasal.
28. The method of claim 27, wherein the topical administration is nasal admini-stration via aerosols, atomizers or nebulizers or that is nasal inhalation via insufflation.
29. Use of nilvadipine for reducing the risk of .beta.-amyloid deposition, .beta.-amyloid neurotoxicity and microgliosis in animals and humans suffering from traumatic brain injury wherein the use begins immediately following the acute head injury.
30. The use according to claim 29, wherein said use comprises use in a human of an amount of nilvadipine of 0.05-20 mg per day.
31. The use according to claim 29, wherein said use comprises use in a human of an amount of nilvadipine of 2-15 mg per day.
32. The use according to claim 29, wherein said use comprises use in a human of an amount of nilvadipine of 4-12 mg per day.
33. The use according to claim 29, wherein said use comprises use in a human of an amount of nilvadipine of about 8 mg per day.
34. The use according to claim 29, wherein said use is for the duration of between one hour to five years.
35. The use according to claim 29, wherein said use is for the duration of between two weeks to three years.
36. The use according to claim 29, wherein said use is for the duration of between six months and twelve months.
37. The use according to claim 29, wherein the use of nilvadipine is for parenteral, oral or intraperitoneal administration.
38. The use according to claim 37 for oral administration, wherein the oral administration is selected from the group consisting of hard or soft shell gelatin capsules, tablets, troches, sachets, lozenges, elixirs, suspensions, syrups, wafers, powders, granules, solutions and emulsions.
39. The use of claim 37 for parenteral administration, wherein the parenteral administration is intravenous, intramuscular, interstitial, intra-arterial, subcutaneous, intraocular, intracranial, intraventricular, intrasynovial, transepithelial, or topical.
40. The use according to claim 37 for parenteral administration, wherein the pareteral administration is transepithelial administration that is transdermal, pulmonary via inhalation, ophthalmic, sublingual or buccal.
41. The use according to claim 37 for parenteral administration wherein the parenteral administration is topical administration that is ophthalmic, dermal, ocular, rectal, or nasal.
42. The use according to claim 37, wherein the topical administration is nasal administration via aerosols, atomizers or nebulizers or that is nasal inhalation via insufflation.
43. Use of nilvadipine for treating transplantable neuronal stem cells or fetal cells prior to transplantation of the stem cells or fetal cells in the central nervous system of an animal or human afflicted with a cerebral amyloidogenic disease.
44. The use according to claim 43, wherein the cerebral amyloidogenic disease is selected from the group consisting of Alzheimer's disease, transmissible spongiform encephalopathy, scrapie, traumatic brain injury, cerebral amyloid angiopathy, and Gerstmann-Straussler-Scheinker syndrome and the use further comprises use of nilvadipine for treating the animal or human after the transplantation.
45. The use according to 44, wherein the use for treating the transplantable neuronal stem cells or fetal cells includes an amount of nilvadipine of 1 nM-3 µM.
46. The use according to claim 43, wherein the use for treating the transplantable neuronal stem cells or fetal cells includes an amount of nilvadipine of 10 nM-2 µM.
47. The use according to claim 43, wherein the use for treating the transplantable neuronal stem cells or fetal cells includes an amount of nilvadipine of 100 nM-1 µM.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US47069403P | 2003-05-15 | 2003-05-15 | |
| US60/470,694 | 2003-05-15 | ||
| PCT/US2004/015417 WO2004110354A2 (en) | 2003-05-15 | 2004-05-17 | Method for reducing amyloid deposition, amyloid neurotoxicity and microgliosis |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CA2525970A1 CA2525970A1 (en) | 2004-12-23 |
| CA2525970C true CA2525970C (en) | 2011-03-22 |
Family
ID=33551420
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA2525970A Expired - Fee Related CA2525970C (en) | 2003-05-15 | 2004-05-17 | Use of nilvadipine for reducing amyloid deposition, amyloid neurotoxicity and microgliosis |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US7732467B2 (en) |
| EP (1) | EP1628663B1 (en) |
| JP (1) | JP4971794B2 (en) |
| CN (1) | CN100444840C (en) |
| AT (1) | ATE437641T1 (en) |
| CA (1) | CA2525970C (en) |
| DE (1) | DE602004022284D1 (en) |
| DK (1) | DK1628663T3 (en) |
| ES (1) | ES2334029T3 (en) |
| HK (1) | HK1092358A1 (en) |
| WO (1) | WO2004110354A2 (en) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2603676A1 (en) * | 2005-01-07 | 2006-07-13 | Roskamp Research Llc | Compounds for inhibiting beta-amyloid production and methods of identifying the compounds |
| PT1874311E (en) * | 2005-04-15 | 2011-11-25 | Res & Innovation S P A | A method for preventing, delaying or reverting abnormal amyloid deposition |
| CA2644240A1 (en) * | 2006-03-01 | 2007-09-13 | Roskamp Research, Llc | Compounds for inhibiting beta-amyloid production |
| EP2120557A4 (en) * | 2006-12-08 | 2010-02-10 | Roskamp Res Llc | Polyhydroquinoline compounds and dihydropyridine compounds for inhibiting beta-amyloid production |
| US8709394B2 (en) * | 2007-09-28 | 2014-04-29 | Ndsu Research Foundation | Antimicrobial polysiloxane materials containing metal species |
| US20100093810A1 (en) * | 2007-10-05 | 2010-04-15 | Alzheimer's Institute Of America, Inc. | Pharmaceutical Compositions for Reducing Amyloid Deposition, Amyloid Neurotoxicity, and Microgliosis |
| TWI500422B (en) * | 2007-10-05 | 2015-09-21 | Alzheimer S Inst Of America Inc | Method for reducing amyloid deposition, amyloid neurotoxicity, and microgliosis with (-)-nilvadipine enantiomer |
| WO2009046338A1 (en) * | 2007-10-05 | 2009-04-09 | Roskamp Research Llc | Method for increasing cerebral blood flow with (+)-nilvadipine enantiomer |
| WO2010132671A1 (en) * | 2009-05-15 | 2010-11-18 | The University Of Kentucky Research Foundation | Treatment of mci and alzheimer's disease |
| EP2311823A1 (en) * | 2009-10-15 | 2011-04-20 | AC Immune S.A. | 2,6-Diaminopyridine compounds for treating diseases associated with amyloid proteins or for treating ocular diseases |
| KR20140128230A (en) | 2013-04-26 | 2014-11-05 | 한국과학기술연구원 | Diagnostic kit for diagnosis of protein aggregation and misfolding related diseases or disorders using dissociation of protein aggregates in blood |
Family Cites Families (52)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4338322A (en) | 1975-07-02 | 1982-07-06 | Fujisawa Pharmaceutical Co., Ltd. | 1,4-Dihydropyridine derivatives, pharmaceutical compositions containing same and methods of effecting vasodilation using same |
| JPS6038322A (en) | 1983-08-11 | 1985-02-27 | Fujisawa Pharmaceut Co Ltd | Easily soluble solid preparation containing dihydropyridine-a substance |
| JPS61129140A (en) | 1984-11-27 | 1986-06-17 | Nitto Electric Ind Co Ltd | Pharmaceutical composition |
| GB8431119D0 (en) | 1984-12-10 | 1985-01-16 | Fujisawa Pharmaceutical Co | Anti-arteriosclerotic composition |
| US4940556A (en) | 1986-01-30 | 1990-07-10 | Syntex (U.S.A.) Inc. | Method of preparing long acting formulation |
| US5001139A (en) | 1987-06-12 | 1991-03-19 | American Cyanamid Company | Enchancers for the transdermal flux of nivadipine |
| DE3877630T2 (en) | 1987-06-12 | 1993-06-03 | American Cyanamid Co | TRANSCUTANEOUS ADMINISTRATION OF PHARMACEUTICALS. |
| US5114946A (en) | 1987-06-12 | 1992-05-19 | American Cyanamid Company | Transdermal delivery of pharmaceuticals |
| US4992445A (en) | 1987-06-12 | 1991-02-12 | American Cyanamid Co. | Transdermal delivery of pharmaceuticals |
| US5045553A (en) | 1987-06-24 | 1991-09-03 | Fujisawa Pharmaceutical Company, Ltd. | Pharmaceutical composition for percutaneous drug absorption and percutaneous drug absorption promoter |
| US4820720A (en) | 1987-08-24 | 1989-04-11 | Alza Corporation | Transdermal drug composition with dual permeation enhancers |
| ES2037179T3 (en) | 1987-11-25 | 1993-06-16 | American Cyanamid Company | SUSTAINED RELEASE SYSTEM (CONTROLLED) FOR DIHYDROPYRIDINE CALCIUM CHANNEL BLOCKERS. |
| US5160734A (en) | 1987-11-25 | 1992-11-03 | American Cyanamid Company | Sustained release delivery system for substituted dihydropyridine calcium channel blockers |
| US4902514A (en) | 1988-07-21 | 1990-02-20 | Alza Corporation | Dosage form for administering nilvadipine for treating cardiovascular symptoms |
| JP3479532B2 (en) | 1989-03-31 | 2003-12-15 | ザ・チルドレンズ・メディカル・センター・コーポレーション | Treatment of AIDS dementia, spinal cord disorders and blindness |
| JP2867462B2 (en) | 1989-09-12 | 1999-03-08 | 藤沢薬品工業株式会社 | Transdermal formulation |
| JPH03117658A (en) | 1989-09-29 | 1991-05-20 | Mazda Motor Corp | External combustion type rotary piston engine |
| JP2920956B2 (en) | 1989-10-06 | 1999-07-19 | 藤沢薬品工業株式会社 | Long-acting tablets containing nilvadipine |
| WO1992003137A1 (en) | 1990-08-23 | 1992-03-05 | The Children's Medical Center Corporation | Treatment of aids dementia, myelopathy, peripheral neuropathy, and vision loss |
| WO1993005770A1 (en) | 1991-09-20 | 1993-04-01 | Fujisawa Pharmaceutical Co., Ltd. | Long-acting preparation |
| JPH05139974A (en) | 1991-11-26 | 1993-06-08 | Fujisawa Pharmaceut Co Ltd | Production of easily soluble solid dispersion containing dihydropyridine a substance |
| DE4141646A1 (en) | 1991-12-17 | 1993-06-24 | Klinge Co Chem Pharm Fab | Synergistic compsn. comprising nilvadipine and captopril - for treatment of hypertension, angina pectoris and coronary insufficiency |
| US5340591A (en) | 1992-01-24 | 1994-08-23 | Fujisawa Pharmaceutical Co., Ltd. | Method of producing a solid dispersion of the sparingly water-soluble drug, nilvadipine |
| DE4229805A1 (en) * | 1992-09-07 | 1994-03-24 | Werner E G Prof Dr Mueller | Treating diseases caused by prion proteins or analogues - with calcium channel antagonists or NMDA antagonists, having cytoprotective effect on brain neurons |
| US5721263A (en) | 1993-06-07 | 1998-02-24 | Takeda Chemical Industries, Ltd. | Pharmaceutical composition for angiotensin II-mediated diseases |
| CA2125251C (en) | 1993-06-07 | 2005-04-26 | Yoshiyuki Inada | A pharmaceutical composition for angiotensin ii-mediated diseases |
| US6334997B1 (en) | 1994-03-25 | 2002-01-01 | Isotechnika, Inc. | Method of using deuterated calcium channel blockers |
| JP3541389B2 (en) | 1996-04-26 | 2004-07-07 | 藤沢薬品工業株式会社 | Ocular tissue peripheral circulation improving agent containing dihydropyridine compound |
| US6271259B1 (en) * | 1996-05-07 | 2001-08-07 | Ito En, Ltd. | Method for improving the brain function, inhibiting glutamate excitotoxicity and rescuing from neuronal death |
| KR100222306B1 (en) | 1996-11-20 | 1999-10-01 | 이병언 | A fast effective nilbadipine preparation and the preparation process thereof |
| EP1085863A4 (en) | 1998-06-08 | 2001-03-28 | Advanced Medicine Inc | Cross-reference to related applications |
| AU4672699A (en) | 1998-06-08 | 1999-12-30 | Theravance, Inc. | Novel sodium channel drugs and uses |
| ES2552639T3 (en) | 1998-07-10 | 2015-12-01 | Novartis Pharma Ag | Combined use of valsartan and calcium channel blockers for therapeutic purposes |
| EP1260232A1 (en) | 2000-03-03 | 2002-11-27 | Fujisawa Pharmaceutical Co., Ltd. | Remedies for malignant tumor-concomitant neurosis and azoor or analogous diseases thereof |
| AU4688301A (en) | 2000-04-11 | 2001-10-23 | Sankyo Co | Stabilized pharmaceutical compositions containing calcium channel blockers |
| JP2001335483A (en) | 2000-05-30 | 2001-12-04 | Nichiko Pharmaceutical Co Ltd | Nilvadipine-containing pharmaceutical peparation |
| DE60127410T2 (en) | 2000-07-27 | 2007-12-13 | Pharmacia Corp. | COMBINATION THERAPY WITH EPOXY-STEROIDAL ALDOSTERONE ANTAGONISTS AND CALCIUM CHANNEL BLOCKS FOR THE TREATMENT OF CONGESTIVE HEART FAILURE |
| JP3968687B2 (en) | 2000-09-13 | 2007-08-29 | 東和薬品株式会社 | Easy absorbable nilvadipine tablets |
| JP3470096B2 (en) | 2000-09-19 | 2003-11-25 | 沢井製薬株式会社 | Nilvadipine-containing easily soluble solid preparation and method for producing the same |
| AU2002229573A1 (en) | 2000-12-19 | 2002-07-01 | Merck Patent Gmbh | Pharmaceutical formulation containing pyrazolo(4,3-D)pyrimidines and antithrombotic agents, calcium-antagonists, prostaglandins or prostaglandin derivatives |
| AU2002227957A1 (en) | 2000-12-19 | 2002-07-01 | Merck Patent Gmbh | Pharmaceutical formulation containing thienopyrimidines and antithrombotics, calcium antagonists, prostaglandins or prostaglandin derivatives |
| US7083642B2 (en) | 2000-12-22 | 2006-08-01 | Avantec Vascular Corporation | Delivery of therapeutic capable agents |
| CA2333494A1 (en) | 2001-02-01 | 2002-08-01 | Vasogen Ireland Limited | Blood brain barrier modulation |
| PT1392287E (en) * | 2001-05-25 | 2007-02-28 | Schering Corp | Use of azetidinone substituted derivatives in the treatment of alzheimer`s disease |
| WO2004034963A2 (en) | 2002-05-17 | 2004-04-29 | Eisai Co., Ltd. | Methods and compositions using cholinesterase inhibitors |
| EG24716A (en) | 2002-05-17 | 2010-06-07 | Novartis Ag | Combination of organic compounds |
| AR040017A1 (en) | 2002-05-17 | 2005-03-09 | Novartis Ag | COMBINATION OF ORGANIC COMPOUNDS |
| KR20130109244A (en) | 2002-05-17 | 2013-10-07 | 노파르티스 아게 | Pharmaceutical composition comprising a renin inhibitor, a calcium channel blocker and a diuretic |
| JP2003146878A (en) | 2002-11-22 | 2003-05-21 | Sawai Pharmaceutical Co Ltd | Readily soluble solid preparation containing nilvadipine, and method for producing the same |
| BR0317747A (en) * | 2002-12-24 | 2005-11-22 | Neurochem Int Ltd | Method of concomitant therapeutic treatment of an individual, pharmaceutical composition, kit, use of a first agent and a second agent, and methods of preventing or treating amyloid-b-related disease, alzheimer's disease and mild cognitive impairment |
| US20050031651A1 (en) | 2002-12-24 | 2005-02-10 | Francine Gervais | Therapeutic formulations for the treatment of beta-amyloid related diseases |
| JP2004002460A (en) | 2003-07-29 | 2004-01-08 | Towa Yakuhin Kk | Method for production of readily absorbable nilvadipine tablets |
-
2004
- 2004-05-17 DK DK04752432.7T patent/DK1628663T3/en active
- 2004-05-17 US US10/847,630 patent/US7732467B2/en active Active
- 2004-05-17 DE DE602004022284T patent/DE602004022284D1/en not_active Expired - Lifetime
- 2004-05-17 CN CNB2004800171974A patent/CN100444840C/en not_active Expired - Fee Related
- 2004-05-17 WO PCT/US2004/015417 patent/WO2004110354A2/en active Search and Examination
- 2004-05-17 JP JP2006533144A patent/JP4971794B2/en not_active Expired - Lifetime
- 2004-05-17 EP EP04752432A patent/EP1628663B1/en not_active Expired - Lifetime
- 2004-05-17 AT AT04752432T patent/ATE437641T1/en not_active IP Right Cessation
- 2004-05-17 ES ES04752432T patent/ES2334029T3/en not_active Expired - Lifetime
- 2004-05-17 CA CA2525970A patent/CA2525970C/en not_active Expired - Fee Related
-
2006
- 2006-08-31 HK HK06109711.3A patent/HK1092358A1/en not_active IP Right Cessation
Also Published As
| Publication number | Publication date |
|---|---|
| WO2004110354A3 (en) | 2005-02-10 |
| JP4971794B2 (en) | 2012-07-11 |
| EP1628663A4 (en) | 2006-05-24 |
| EP1628663B1 (en) | 2009-07-29 |
| JP2007501277A (en) | 2007-01-25 |
| ES2334029T3 (en) | 2010-03-04 |
| US7732467B2 (en) | 2010-06-08 |
| CN100444840C (en) | 2008-12-24 |
| US20050009885A1 (en) | 2005-01-13 |
| CA2525970A1 (en) | 2004-12-23 |
| CN1809352A (en) | 2006-07-26 |
| EP1628663A2 (en) | 2006-03-01 |
| ATE437641T1 (en) | 2009-08-15 |
| DE602004022284D1 (en) | 2009-09-10 |
| HK1092358A1 (en) | 2007-02-09 |
| DK1628663T3 (en) | 2010-03-08 |
| WO2004110354A2 (en) | 2004-12-23 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Jacobsen et al. | Current concepts in therapeutic strategies targeting cognitive decline and disease modification in Alzheimer's disease | |
| US20100324079A1 (en) | Medicament for prophylaxis and treatment of Alzheimer disease | |
| CA2525970C (en) | Use of nilvadipine for reducing amyloid deposition, amyloid neurotoxicity and microgliosis | |
| US11382893B2 (en) | (3aR)-1,3a,8-trimethyl-1,2,3,3a,8,8a-hexahydropyrrolo[2,3-b]indol-5-yl phenylcarbamate and methods of treating or preventing neurodegeneration | |
| US20100267733A1 (en) | Synergistic Modulation of Microglial Activation by Nicotine and THC | |
| US20060223790A1 (en) | Modulation of Microglial by Nicotinic Medications | |
| US7674597B2 (en) | Signaling intermediates in an in vitro model of Alzheimer's disease | |
| CA2701620C (en) | Method for reducing amyloid deposition, amyloid neurotoxicity, and microgliosis with (-)-nilvadipine enantiomer | |
| US20100093810A1 (en) | Pharmaceutical Compositions for Reducing Amyloid Deposition, Amyloid Neurotoxicity, and Microgliosis | |
| Martin-Avila et al. | Clearing truncated tau protein restores neuronal function and prevents microglia activation in tauopathy mice | |
| WO2009046338A1 (en) | Method for increasing cerebral blood flow with (+)-nilvadipine enantiomer |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request | ||
| MKLA | Lapsed |
Effective date: 20220301 |
|
| MKLA | Lapsed |
Effective date: 20200831 |